Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q665725> ?p ?o }
Showing triples 1 to 49 of
49
with 100 triples per page.
- Q665725 subject Q5920511.
- Q665725 subject Q7170959.
- Q665725 subject Q8808791.
- Q665725 subject Q8965786.
- Q665725 abstract "Vernakalant (INN; codenamed RSD1235, proposed tradenames Kynapid and Brinavess) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation. It was initially developed by Cardiome Pharma, and the intravenous formulation was bought for further development by Merck in April 2009. In September 2012, Merck terminated its agreements with Cardiome and has consequently returned all rights of the drug back to Cardiome.On 11 December 2007, the Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted to recommend the approval of vernakalant, but in August 2008 the FDA judged that additional information was necessary for approval. The drug (under brand name Brinavess) was approved in Europe on 1 September 2010.An oral formulation underwent Phase II clinical trials between 2005 and 2008.".
- Q665725 atcPrefix "C01".
- Q665725 atcSuffix "BG11".
- Q665725 casNumber "794466-70-9".
- Q665725 casSupplemental "(HCl)".
- Q665725 fdaUniiCode "9G468C8B13".
- Q665725 iupacName "(3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)".
- Q665725 iupacName "ethoxy]cyclohexyl}pyrrolidin-3-ol".
- Q665725 pubchem "9930049".
- Q665725 thumbnail Vernakalant.svg?width=300.
- Q665725 wikiPageWikiLink Q1073121.
- Q665725 wikiPageWikiLink Q1074839.
- Q665725 wikiPageWikiLink Q12074763.
- Q665725 wikiPageWikiLink Q14865830.
- Q665725 wikiPageWikiLink Q204711.
- Q665725 wikiPageWikiLink Q241549.
- Q665725 wikiPageWikiLink Q247489.
- Q665725 wikiPageWikiLink Q30612.
- Q665725 wikiPageWikiLink Q420060.
- Q665725 wikiPageWikiLink Q423778.
- Q665725 wikiPageWikiLink Q424960.
- Q665725 wikiPageWikiLink Q5038336.
- Q665725 wikiPageWikiLink Q56002.
- Q665725 wikiPageWikiLink Q5920511.
- Q665725 wikiPageWikiLink Q640448.
- Q665725 wikiPageWikiLink Q7170959.
- Q665725 wikiPageWikiLink Q815819.
- Q665725 wikiPageWikiLink Q824258.
- Q665725 wikiPageWikiLink Q8808791.
- Q665725 wikiPageWikiLink Q8965786.
- Q665725 atcPrefix "1.0".
- Q665725 atcSuffix "BG11".
- Q665725 casNumber "794466".
- Q665725 iupacName "-1".
- Q665725 iupacName "ethoxy]cyclohexyl}pyrrolidin-3-ol".
- Q665725 pubchem "9930049".
- Q665725 unii "9".
- Q665725 type ChemicalSubstance.
- Q665725 type Drug.
- Q665725 type ChemicalObject.
- Q665725 type Thing.
- Q665725 type Q8386.
- Q665725 comment "Vernakalant (INN; codenamed RSD1235, proposed tradenames Kynapid and Brinavess) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation. It was initially developed by Cardiome Pharma, and the intravenous formulation was bought for further development by Merck in April 2009.".
- Q665725 label "Vernakalant".
- Q665725 depiction Vernakalant.svg.